Vitamins 58.2
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hepcidin Therapeutics
pharmaceuticals Review Hepcidin Therapeutics Angeliki Katsarou and Kostas Pantopoulos * Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-(514)-340-8260 (ext. 25293) Received: 3 November 2018; Accepted: 19 November 2018; Published: 21 November 2018 Abstract: Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art. Keywords: iron metabolism; hepcidin; ferroportin; hemochromatosis; anemia 1. Systemic Iron Homeostasis Iron is an essential constituent of cells and organisms and participates in vital biochemical activities, such as DNA synthesis, oxygen transfer, and energy metabolism. The biological functions of iron are based on its capacity to interact with proteins and on its propensity to switch between the ferrous (Fe2+) and ferric (Fe3+) oxidation states. -
|||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
|||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al. -
(12) United States Patent (10) Patent No.: US 7.625,916 B2 Kawasugi (45) Date of Patent: Dec
US00762.5916B2 (12) United States Patent (10) Patent No.: US 7.625,916 B2 Kawasugi (45) Date of Patent: Dec. 1, 2009 (54) MEDICINAL COMPOSITION (56) References Cited (76) Inventor: Kaname Kawasugi, 26-10-405, U.S. PATENT DOCUMENTS Higashi-oi 5-chome, Shinagawa-ku 3,502,674. A 3/1970 Takamizawa et al. Tokyo (JP) 140-0011 4,687,777 A * 8/1987 Meguro et al. .............. 514,342 5,002.953 A * 3/1991 Hindley ......... ... 514,275 c - r 5,977.073 A * 1 1/1999 Khaled ........................ 514, 19 (*) Notice: Subject to any disclaimer, the term of this 6,166,219 A * 12/2000 Yamasaki et al. ........ 548/309.4 patent is extended or adjusted under 35 6.251926 B1* 6/2001 Momose et al. ............. 514,364 U.S.C. 154(b) by 122 days. 6,660,293 B2 * 12/2003 Giordano et al. ............ 424/439 (21) Appl. No.: 10/572,557 FOREIGN PATENT DOCUMENTS FR 2832O64 A1 * 5, 2003 (22) PCT Filed: Sep. 17, 2003 WO O2/O51441 T 2002 (86). PCT No.: PCT/UP03/11847 OTHER PUBLICATIONS Tamai, Hiroshi. “Diabetes and Vitamin Levels', Japanese Journal of S371 (c)(1), Clinical Medicine, vol. 57, No. 10, pp. 200-203, 1999. (2), (4) Date: Mar. 17, 2006 Hashizume, Naotaka, “Vitamin B1 Deficiency”. Igaku no Ayumi, vol. 198, No. 13, pp. 949-952, 2001. (87) PCT Pub. No.: WO2005/027967 * cited by examiner PCT Pub. Date: Mar. 31, 2005 Primary Examiner Kevin Weddington (74) Attorney, Agent, or Firm Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P. (65) Prior Publication Data (57) ABSTRACT US 2007/O 10591.0 A1 May 10, 2007 A medicinal composition which comprises an insulin resis 51) Int. -
United States Patent (19) 11 Patent Number: 6,129,925 Kido Et Al
USOO6129925A United States Patent (19) 11 Patent Number: 6,129,925 Kido et al. (45) Date of Patent: *Oct. 10, 2000 54 CONTAINER FILLED WITH INFUSION 5,770,233 6/1998 Kido et al. .............................. 424/641 LIQUIDS AND INFUSION PREPARATION FOREIGN PATENT DOCUMENTS 75 Inventors: Takae Kido; Shigeo Ii; Shun-ichi Abe; 0510687 10/1992 European Pat. Off.. Kazumasa Yokoyama, all of Osaka, 58-162515 9/1982 Japan. Japan 58-162517 9/1983 Japan. 61-058560 3/1986 Japan. 73 Assignee: Yoshitomi Pharmaceutical Industries, 62-135421 6/1987 Japan. Ltd., Osaka, Japan OTHER PUBLICATIONS * Notice: This patent issued on a continued pros Derwent Abstract N89-244721, abstracting JP 1-240469, ecution application filed under 37 CFR 1989. 1.53(d), and is subject to the twenty year Chemical Abstracts 99:146124J, 1983. patent term provisions of 35 U.S.C. Chemical Abstracts 69:89709h (1968). 154(a)(2). Primary Examiner S. Mark Clardy Assistant Examiner Kathryne E. Shelborne 21 Appl. No.: 09/032,843 Attorney, Agent, or Firm Sughrue, Mion, Zinn, Macpeak 22 Filed: Mar. 2, 1998 & Seas, PLLC 57 ABSTRACT Related U.S. Application Data An object of the present invention is to provide an infusion 60 Division of application No. 08/437,330, Apr. 21, 1995, Pat. preparation set (a container filled with infusion liquids) No. 5,770,233, which is a continuation-in-part of application useful for preparation of an infusion liquid containing No. PCT/JP93/01521, Oct. 21, 1993. Sugars, amino acids, electrolytes, a fat emulsion and Vita 30 Foreign Application Priority Data mins. The present invention is constituted by the use of a container having two compartments which are separated Oct. -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX -
Product Infomation | Nabolin EB
本製品は日本国法に基づき製造販売されたものです。 製品および文書は日本国外の法規に準じているわけではありません。 本文書は、日本語の製品情報を翻訳した文書です。使用前に必ずお読みください。 また、必要な時に読めるように大切に保管してください。 This product has been manufactured and sold based on Japanese law. Neither the product nor this informational leaflet will necessarily conform to the laws of countries outside of Japan. This leaflet contains a translation of product information from Japanese. You should read this written explanation before using the product. Store this informational leaflet safely so that it can be read when necessary. Discovering everything from prevention to cure Category-3 OTC drug Relief of stiff shoulder, lumbago, and numbness in the limbs Nabolin EB Stiffness of the shoulders and lumbago occur due to excessive loads on the shoulder or low back. If you stay in the same posture or try to maintain a difficult posture, the muscles in your shoulders or low back may harden, damaging the peripheral nerves, and causing stiffness or pain. The main ingredient of ナボリン EB 錠 is activated vitamin B12 (mecobalamin), which repairs peripheral nerve damage and relieves stiff shoulder and lumbago. Mecobalamin is one of the four types of vitamin B12, an activated type of vitamin B12 that is easy for the body to Recommended retail price Package use and acts directly on peripheral nerves. ナボリン EB (tax included) 錠 also contain vitamins B1, B6, and E, which have an 45 tablets ¥2,592 effect on stiff shoulders and lumbago that appear due to muscle fatigue or poor circulation. 120 tablets ¥6,264 Related website ナボリン Club (in Japanese) Indications Relief of the following symptoms: stiffness in the shoulder and neck, lumbago, neuralgia, and numbness in the limbs (A physician or pharmacist should be consulted if there is no improvement after about 1 month of administration) Dosage and Administration Take the following doses with cold or hot water after a meal. -
Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
Nutritional Approaches to Combat Oxidative Stress in Alzheimer's
REVIEWS: CURRENT TOPICS Journal of Nutritional Biochemistry 13 (2002) 444–461 Nutritional approaches to combat oxidative stress in Alzheimer’s disease D. Allan Butterfielda,*, Alessandra Castegnaa, Chava B. Pocernicha, Jennifer Drakea, Giovanni Scapagninib, Vittorio Calabresec aDepartment of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506-0055, USA bBlanchette Rockefeller Neurosciences Institute, West Virginia University, Rockville, MD 20850, USA cSection of Biochemistry and Molecular Biology, Department of Chemistry, Faculty of Medicine, University of Catania, Catania, Italy Received 12 March 2002; received in revised form 4 April 2002; accepted 17 April 2002 Abstract Alzheimer’s disease (AD) brains are characterized by extensive oxidative stress. Additionally, large depositions of amyloid -peptide (A) are observed, and many researchers opine that A is central to the pathogenesis of AD. Our laboratory combined these two observations in a comprehensive model for neurodegeneration in AD brains centered around A-induced oxidative stress. Given the oxidative stress in AD and its potentially important role in neurodegeneration, considerable research has been conducted on the use of antioxidants to slow or reverse the pathology and course of AD. One source of antioxidants is the diet. This review examines the literature of the effects of endogenous and exogenous, nutritionally-derived antioxidants in relation to AD. In particular, studies of glutathione and other SH-containing antioxidants, vitamins, and polyphenolic compounds and their use in AD and modulation of A-induced oxidative stress and neurotoxicity are reviewed. © 2002 Elsevier Science Inc. All rights reserved. Keywords: Alzheimer’s disease; Antioxidants; Glutathione; Polyphenols; Vitamins; Oxidative stress; Amyloid beta-peptide; Cellular response genes 1. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0203126 A1 Park Et Al
US 20100203126A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0203126 A1 Park et al. (43) Pub. Date: Aug. 12, 2010 (54) MULTILAYERED VITAMIN COMPLEX Publication Classification TABLET CONTAINING UBDECARENONE (51) Int. Cl. A69/20 (2006.01) A6II 3/34 (2006.01) (76) Inventors: Jong-Woo Park, Gyeonggi-do A 6LX 3L/355 (2006.01) (KR); Jin-Woo Han, Gyeonggi-do A6II 3L/23 (2006.01) (KR); Yae-Young Choi, Seoul (KR) A63L/7056 (2006.01) A6II 3/4406 (2006.01) A63/675 (2006.01) Correspondence Address: A6II 3L/22 (2006.01) DCKSTEIN SHAPRO LLP A633/30 (2006.01) 1825. EYE STREET NW A633/26 (2006.01) Washington, DC 20006-5403 (US) A633/42 (2006.01) A6IR 9/28 (2006.01) (52) U.S. Cl. ......... 424/465: 514/474; 424/464: 514/458: (21) Appl. No.: 12/668,328 514/552; 514/52: 514/355; 514/89: 514/678: 424/643; 424/646; 424/602; 424/474 (22) PCT Filed: Jul. 11, 2008 (57) ABSTRACT The present invention relates to a multi-layered vitamin/min eral complex tablet having enhanced stability of ubide (86). PCT No.: PCT/KRO8/04111 carenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients S371 (c)(1), decreasing the stability of ubidecarenone are contained in an (2), (4) Date: Jan. 8, 2010 additional layer separated from the first layer. The method is a convenient process, and the formulation prepared by the method can maintain a high content of ubidecarenone during (30) Foreign Application Priority Data long-term storage, thereby providing a simultaneous intake of ubidecarenone and nutritional ingredients such as various Jul. -
Wo 2008/127291 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US). -
Novel Therapies in Acute Kidney Injury
NOVEL THERAPIES IN ACUTE KIDNEY INJURY A THESIS PRESENTED BY Dr SHOAB AHMED MEMON Registered at Bart’s and The London School of Medicine & Dentistry Queen Mary University of London, Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom For The degree of Doctor of Philosophy. 1 DECLARATION: I declare that this thesis is my own work and has not been submitted in any form for another degree or diploma at any university or other institution of tertiary education. Information derived from the work of others has been acknowledged in the text and a list of references is given. 1st July 2014 ____________________________ __________________ (Signature) (Date) 2 Contents List of figures: ............................................................................................................... 7 List of Tables ................................................................................................................. 8 Units and symbols ...................................................................................................... 13 Routes of administration and statistical terms......................................................... 14 Abstract ........................................................................................................................ 15 Acknowledgements ..................................................................................................... 17 CHAPTER 1 .................................................................................................................